Topic:
Financials
Latest Headlines
Latest Headlines
Teva agrees to lift the veil on executive pay
Want to know how much Jeremy Levin makes? You'll soon find out. The numbers on Teva Pharmaceutical Industries' CEO pay will finally go public, now that the company has settled a lawsuit from investors angry about the compensation secrecy.
Vertos hauls in $23M for spinal device
California's Vertos Medical has closed $23 million in financing, cash the company will use to expand the market for its pain-reducing spinal surgery device.
Mirabilis nabs up to $13M for uterine fibroid device
Washington's Mirabilis Medica has closed $7 million in financing for its ultrasound-based uterine fibroid treatment, part of a Series A that could reach $13 million.
Use prescription meds properly, save $200 billion a year
The good news from IMS Institute for Healthcare Informatics: Using prescription medicines properly could save $200 billion in annual U.S. healthcare costs. More good news, at least for the pharma business: The institute's ideas for saving money don't all translate to less spending on drugs, branded or otherwise.
Exact raising $63.7M on rocky road to FDA approval
Exact Sciences is looking to haul in $63.7 million through a stock sale, cash the company needs to get its stool-based cancer diagnostic through the FDA process and onto U.S. shelves.
Amaranth's dissolving cardiac stent drives $25M fundraising round
Bioresorbable cardiovascular stents are gaining momentum and drawing more investor interest. This time, the spotlight falls on Amaranth Medical, which is well underway with plans to raise a $25 million Series B funding round.
Veniti reels in $9.7M for vein treatment device work
Veniti, a Missouri device startup developing venous disease treatments, has nailed down more than $9.7 million of an anticipated $12 million round of venture financing from 15 investors, according to a regulatory filing.
Startup NeuroTronik hauls in $13.1M for heart device
Within a year of its launch, North Carolina's NeuroTronik has closed a $13.1 million Series A to develop a device that treats heart failure with neuromodulation.
More insider trading charges from Sanofi's Chattem buyout
On Tuesday, the SEC filed civil complaints against two brothers accused of buying stock based on secret knowledge of the then-upcoming takeover--the 8th case the Commission has brought against insider trading connected to that deal, it says.
Thermo Fisher details plans for $2.2B common-stock sale
Thermo Fisher has released details concerning the execution of a $2.2 billion sale of common stock--a massive undertaking designed to help cover its $13.6 billion bid to buy Life Technologies.
